Major adc companies, current clinical trials, recent patents issued and patent applications, and cost analysis of drug therapy

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 17, Issue , 2015, Pages 153-175

  Wang, Jeffrey ^a   Watanabe, Jonathan Hirohiko ^b  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; METHOTREXATE; PINATUZUMAB VEDOTIN; RITUXIMAB;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG INDUSTRY; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; STOMACH CANCER; T CELL LYMPHOMA;

EID: 84940869920     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-3-319-13081-1_9     Document Type: Article

References (35)

1. Arnon R, Sela M (1982) In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev 62:5–27
2. Astellas R&D Pipeline (2014, Aug) http://wwwastellascom/en/ir/library/pdf/1q2015_rd_enpdf. Accessed 6 Aug 2014
3. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, G. Garcia-Manero, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H (2014) Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 89:964–968
4. Boyd KA, Briggs AH, Paul J, Iveson T, Midgely R, Harkin A, Bates G, Alexander L, Cassidy J (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials 12:A41
5. Canellos GP (2012) Brentuximabvedotin and panobinostat: new drugs for Hodgkin’s lymphoma– can they make one of medical oncology's chemotherapy success stories more successful? J Clin Oncol 30:2171–2172
6. Center for Medicare and Medicaid Services (2013) Medicare Part B drug average sales price files. Available at http://www.cms.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/ downloads/2013-October-ASP-Pricing-File.zip. Accessed July 2014
7. Cutler D (2004) Your Money or Your Life: Strong Medicine for America’s Health Care System. Oxford University Press, New York, USA
8. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185
9. Drummond MF, O’Brien B, Stoddart GL, Torrance GW (1997) Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK
10. FDA (2010) Mylotarg (gemtuzumab ozogamicin): market withdrawal. http://www.fda.gov/Safe-ty/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458.htm. Accessed 6 Aug 2014
11. Fojo T, Grady C (2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $ 440 billion question. J Natl Cancer Inst 101:1044–1048
12. Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R (2014) Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized Phase III children’s oncology group trial AAML0531. J Clin Oncol 32:3021–3032
13. Goldenberg MM (2013) Pharmaceutical approval update. PT 38:246–258
14. Goozner M (2004) The $ 800 million pill: the truth behind the cost of new drugs. University of California Press, Oakland, California, USA
15. Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Recher C, Chilton L, Moorman AV, Burnett AK (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986–996
16. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA (2013) Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31:1157–1163
17. Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R, Sela M (1975) The covalent binding of dau-nomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res 35:1175–1181
18. Hurwitz E, Arnon R, Sahar E, Danon Y (1983) A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro. Ann N Y Acad Sci 417:125–136
19. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sli-wkowski MX, Scheller RH, Polakis P, Mallet W (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925–932
20. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA (2013) Cancer drugs in the United States: Jus-tum Pretium–the just price. J Clin Oncol 31:3600–3604
21. Kharfan-Dabaja MA (2014) A new dawn for gemtuzumab ozogamicin? Lancet Oncol 15:913–914
22. Lambert JM, Chari RV (2014) Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 57:6949–6964
23. Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK (2013) Brentuximab vedotin: a CD30-direct-ed antibody-cytotoxic drug conjugate. Pharmacotherapy 33:93–104
24. O’Hear C, Rubnitz JE (2014) Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback? Expert Rev Hematol 7:427–429
25. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR (2014) Site-specific antibody drug conjugates for cancer therapy. mAbs 6:34–45
26. Pazdur R (2008) Endpoints for assessing drug activity in clinical trials. Oncologist 1 (Suppl 2):19–21
27. Ross HJ, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, McCune DE, Rosenberg AH, Baron AD, Grove LE, Thorn MD, Miller DM, Drachman JG, Rudin CM (2006) A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer 54:69–77
28. Rowland GF, O'Neill GJ, Davies DA (1975) Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage. Nature 255:487–488
29. Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P (2010) The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One 5:e8933
30. Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30:631–637
31. Smith S (2001) Technology evaluation: SGN-15, Seattle Genetics Inc. Curr Opin Mol Ther 3:295–302
32. Sullivan SD (2008) The promise of specialty pharmaceuticals: are they worth the price? J Manag Care Pharm 14:S3–6
33. Thayer AM (2014) Building antibody-drug conjugates. Chem Eng News 92:13–21
34. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 12:CD003407
35. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vo s S, A. Forero-Torres, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab ve-dotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183–2189